ABBOTINDIA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | ABBOTINDIA | Market Cap | 56,509 Cr. | Current Price | 26,515 ₹ | High / Low | 37,000 ₹ |
| Stock P/E | 37.1 | Book Value | 1,888 ₹ | Dividend Yield | 1.79 % | ROCE | 46.2 % |
| ROE | 35.7 % | Face Value | 10.0 ₹ | DMA 50 | 27,214 ₹ | DMA 200 | 28,872 ₹ |
| Chg in FII Hold | 0.03 % | Chg in DII Hold | -0.11 % | PAT Qtr | 376 Cr. | PAT Prev Qtr | 415 Cr. |
| RSI | 44.5 | MACD | -137 | Volume | 10,670 | Avg Vol 1Wk | 8,728 |
| Low price | 26,000 ₹ | High price | 37,000 ₹ | PEG Ratio | 1.77 | Debt to equity | 0.05 |
| 52w Index | 4.68 % | Qtr Profit Var | 4.21 % | EPS | 717 ₹ | Industry PE | 27.2 |
📊 Analysis: Abbott India (ABBOTINDIA) demonstrates strong fundamentals with excellent ROCE (46.2%) and ROE (35.7%), supported by a nearly debt-free balance sheet (Debt-to-equity 0.05). The company has consistent profitability with EPS of ₹717 and a healthy dividend yield of 1.79%. Valuations are stretched with a P/E of 37.1 compared to industry average of 27.2, and PEG ratio of 1.77 suggests moderate overvaluation relative to growth. Quarterly PAT declined slightly (₹376 Cr. vs ₹415 Cr.), showing earnings moderation. Technical indicators (RSI 44.5, MACD negative) suggest near-term weakness, with price trading below DMA 50 and DMA 200.
💰 Entry Price Zone: Ideal entry would be in the ₹25,000–₹26,000 range, closer to the 52-week low (₹26,000) and valuation comfort. Current price (₹26,515) is near this zone, making accumulation favorable for long-term investors.
📈 Exit / Holding Strategy: If already holding, Abbott India is a strong candidate for long-term investment (5+ years) given its efficiency metrics and stable dividend policy. Partial profit booking can be considered near ₹30,000–₹32,000. Maintain stop-loss around ₹25,000 to protect capital. Long-term holding is justified as the company’s fundamentals remain robust despite short-term earnings moderation.
✅ Positive
- High ROCE (46.2%) and ROE (35.7%) indicate strong efficiency.
- Debt-to-equity ratio of 0.05 ensures financial stability.
- Healthy dividend yield of 1.79% provides shareholder returns.
- EPS of ₹717 reflects strong earnings base.
⚠️ Limitation
- P/E of 37.1 is higher than industry average of 27.2.
- PEG ratio of 1.77 suggests moderate overvaluation.
- Technical weakness with MACD negative and RSI below 50.
📉 Company Negative News
- Quarterly PAT declined from ₹415 Cr. to ₹376 Cr. (-4.21%).
- DII holdings decreased (-0.11%), showing reduced domestic institutional confidence.
📈 Company Positive News
- FII holdings increased slightly (+0.03%), reflecting foreign investor interest.
- Strong fundamentals with consistent dividend payout.
🏭 Industry
- Industry P/E is 27.2, lower than Abbott India’s valuation.
- Pharmaceutical sector demand remains resilient, supported by healthcare growth in India.
🔎 Conclusion
Abbott India is a fundamentally strong company with excellent efficiency metrics and stable dividends, making it a good candidate for long-term investment. Fresh entry is favorable near ₹25,000–₹26,000. Existing investors can hold for 5+ years, with partial profit booking near ₹30,000–₹32,000. Long-term prospects remain positive, supported by strong fundamentals and sector resilience.